Fig 2: ADORA2B expression level in subgroups of patients with LUAD. Relative expression of ADORA2B in normal and different classifications of LUAD tissues. (A) Sample types, (B) individual cancer stages, (C) patient’s race, (D) patient’s gender, (E) patient’s age, (F) patient’s smoking habits, (G) nodal metastasis status, and (H) TP53 mutation status. *p < 0.05 and ***p < 0.001 are statistically significant.

Fig 3: Knockdown of ADORA2B inhibited the proliferation and metastasis of LUAD cells. (A) The cell viability of LUAD cells transfected with control or ADORA2B siRNA was detected by the CCK-8 assay. (B) The wound healing assay was used to examine the effect of ADORA2B siRNA on A549 cell migration for 48 h (magnification: ×40). (C) Relative protein expressions of proliferative (cyclin D1 and PCNA) and metastatic (N-cadherin and vimentin) markers were determined by western blotting. (D) Protein quantitative statistics. *p < 0.05, **p < 0.01, and ***p < 0.001 are statistically significant.

Fig 4: Frequency and type of ADORA2B alterations in LUAD. (A) OncoPrint of ADORA2B alterations in LUAD (cBioPortal) and (B) plots of ADORA2B alterations in LUAD with clinical attributes and mutations (cBioPortal).

Fig 5: Genes associated with ADORA2B expression. (A) Biological interaction network of ADORA2B. (B) Differentially expressed genes correlated with ADORA2B (LinkedOmics). (a) Correlations between ADORA2B and differentially expressed genes in LUAD were analyzed with Pearson’s correlation coefficient. (b) Heat map of genes positively correlated with ADORA2B in LUAD. (c) Heat map of genes negatively correlated with ADORA2B in LUAD. (C) Gene expression correlation analysis of ADORA2B and ADORA2B-correlated genes (LinkedOmics). Pearson correlation of ADORA2B expression with that of (a) ANXA1, (b) ITGA3, (c) S100A6, (d) KDM2B, (e) NEB, and (f) CBFA2T2 (n = 515).